PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
RXRX vs. RLAY
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between RXRX and RLAY is 0.52, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.


-0.50.00.51.00.5

Performance

RXRX vs. RLAY - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Recursion Pharmaceuticals, Inc. (RXRX) and Relay Therapeutics, Inc. (RLAY). The values are adjusted to include any dividend payments, if applicable.

-85.00%-80.00%-75.00%-70.00%JulyAugustSeptemberOctoberNovemberDecember
-80.73%
-87.24%
RXRX
RLAY

Key characteristics

Sharpe Ratio

RXRX:

-0.42

RLAY:

-0.72

Sortino Ratio

RXRX:

-0.15

RLAY:

-1.31

Omega Ratio

RXRX:

0.98

RLAY:

0.86

Calmar Ratio

RXRX:

-0.42

RLAY:

-0.65

Martin Ratio

RXRX:

-0.79

RLAY:

-1.49

Ulcer Index

RXRX:

45.90%

RLAY:

40.63%

Daily Std Dev

RXRX:

85.82%

RLAY:

83.40%

Max Drawdown

RXRX:

-88.97%

RLAY:

-93.24%

Current Drawdown

RXRX:

-85.41%

RLAY:

-93.24%

Fundamentals

Market Cap

RXRX:

$2.77B

RLAY:

$753.22M

EPS

RXRX:

-$1.54

RLAY:

-$2.61

Total Revenue (TTM)

RXRX:

$65.18M

RLAY:

$10.01M

Gross Profit (TTM)

RXRX:

$1.96M

RLAY:

$5.87M

EBITDA (TTM)

RXRX:

-$355.84M

RLAY:

-$389.45M

Returns By Period

In the year-to-date period, RXRX achieves a -38.84% return, which is significantly higher than RLAY's -62.22% return.


RXRX

YTD

-38.84%

1M

-0.17%

6M

-31.86%

1Y

-38.72%

5Y*

N/A

10Y*

N/A

RLAY

YTD

-62.22%

1M

-10.73%

6M

-40.06%

1Y

-61.34%

5Y*

N/A

10Y*

N/A

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

RXRX vs. RLAY - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Recursion Pharmaceuticals, Inc. (RXRX) and Relay Therapeutics, Inc. (RLAY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for RXRX, currently valued at -0.42, compared to the broader market-4.00-2.000.002.00-0.42-0.72
The chart of Sortino ratio for RXRX, currently valued at -0.15, compared to the broader market-4.00-2.000.002.004.00-0.15-1.31
The chart of Omega ratio for RXRX, currently valued at 0.98, compared to the broader market0.501.001.502.000.980.86
The chart of Calmar ratio for RXRX, currently valued at -0.42, compared to the broader market0.002.004.006.00-0.42-0.68
The chart of Martin ratio for RXRX, currently valued at -0.79, compared to the broader market-5.000.005.0010.0015.0020.0025.00-0.79-1.49
RXRX
RLAY

The current RXRX Sharpe Ratio is -0.42, which is higher than the RLAY Sharpe Ratio of -0.72. The chart below compares the historical Sharpe Ratios of RXRX and RLAY, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-0.80-0.60-0.40-0.200.000.200.400.60JulyAugustSeptemberOctoberNovemberDecember
-0.42
-0.72
RXRX
RLAY

Dividends

RXRX vs. RLAY - Dividend Comparison

Neither RXRX nor RLAY has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

RXRX vs. RLAY - Drawdown Comparison

The maximum RXRX drawdown since its inception was -88.97%, roughly equal to the maximum RLAY drawdown of -93.24%. Use the drawdown chart below to compare losses from any high point for RXRX and RLAY. For additional features, visit the drawdowns tool.


-90.00%-85.00%-80.00%-75.00%JulyAugustSeptemberOctoberNovemberDecember
-85.41%
-89.05%
RXRX
RLAY

Volatility

RXRX vs. RLAY - Volatility Comparison

Recursion Pharmaceuticals, Inc. (RXRX) has a higher volatility of 35.51% compared to Relay Therapeutics, Inc. (RLAY) at 21.12%. This indicates that RXRX's price experiences larger fluctuations and is considered to be riskier than RLAY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


10.00%20.00%30.00%40.00%50.00%JulyAugustSeptemberOctoberNovemberDecember
35.51%
21.12%
RXRX
RLAY

Financials

RXRX vs. RLAY - Financials Comparison

This section allows you to compare key financial metrics between Recursion Pharmaceuticals, Inc. and Relay Therapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2024 PortfoliosLab